Sultan's Score: A Novel Predictive Score to Predict Complete Response Following Drug-Eluting Bead Chemoembolization.

BACKGROUND

Transcatheter arterial chemoembolization (TACE) is a well-known standard treatment for hepatocellular carcinoma (HCC); however, the effectiveness of this treatment can vary among patients.

OBJECTIVES

This study aimed to develop a novel imaging-based prediction score (Sultan's score) to predict complete response after treatment.

METHODS

From January 2015 to 2021, 41 patients with solitary HCC, admitted at King Saud University Medical City, Riyadh, Saudi Arabia, were treated with drug-eluting TACE (DEBTACE). Clinical data, tumor details, treatment specifics, and outcomes were gathered retrospectively. Sultan's score incorporates five imaging-based elements, namely, well-defined tumor borders, presence of tumor capsule, tumor size, arterial hyper enhancement, and hypertrophic arterial feeder. The cut-off value of Sultan's score was determined by calculating the maximum Youden index using the receiver operating characteristic curve to accurately predict complete treatment response to DEBTACE.

RESULTS

Following two DEBTACE sessions, 28 (68.3%) and 13 (31.7%) patients showed complete and partial responses, respectively. The mean ± standard deviation and median (interquartile range) of the Sultan's score in patients with a complete treatment response were 3.93 ± 0.72 and 4 (4-4), and the corresponding values in patients with a partial response were 2.77 (0.93) and 3 (2-3.5), respectively. A cut-off value of 3.5 for the Sultan's score had a sensitivity and specificity of 78.6% and 76.9%, respectively, in predicting a complete treatment response. The area under the curve was 0.827 (95% confidence interval: 0.688-0.966).

CONCLUSIONS

We developed a novel imaging-based scoring system (Sultan's score) for predicting complete response in patients with HCC following DEBTACE.